http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S5780319-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a98cb1b197f761c87cd3caf32bc247e2 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C57-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C59-347 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C59-147 |
| filingDate | 1980-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76736063d1578c38e1e0bd7537ea3974 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_064bd7ebb1a2490902e5e17995f5ab83 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b826621fff1da2042301939862c77e6 |
| publicationDate | 1982-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-S5780319-A |
| titleOfInvention | Anti-tumor agent having reduced toxicity |
| abstract | PURPOSE:To prepare the titled anti-tumor agent by compounding a 5-fluorouracil derivative with a specific carboxylic acid as a toxicity-reducing agent. CONSTITUTION:The titled agent contains the carboxylic acid derivative of formula (R1 is amino, formyl, etc.; R2 is H or amino; n is 0 or 1) (e.g. ureidopropionic acid) or its salt, and a 5-fluorouracil derivative[e.g. 1-(2-tetrahydrofuryl)- 5-fluorouracil]. 5-Fluorouracil is a nucleic acid antimetabolite having excellent effect especially against adenocarcinoma, and at the same time, remarkable toxicity and side effects. The carboxylic acid derivative of formula and its salt are effective to remarkably reducing the toxicity of the 5-fluorouracil derivative without lowering its anti-tumor activity, and accordingly, increase the tolerance dose of the 5-fluorouracil derivative and imrpve the anti-tumor effect compared with the separate administration. The amount of the carboxylic acid derivative is 1-5pts.wt. per 1pt.wt. of the 5-fluorouracil derivative. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9204028-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9315729-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H07117552-A |
| priorityDate | 1980-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.